Silence Therapeutics (NASDAQ:SLN) Now Covered by Analysts at The Goldman Sachs Group

The Goldman Sachs Group initiated coverage on shares of Silence Therapeutics (NASDAQ:SLN) in a report issued on Tuesday, Marketbeat Ratings reports. The firm set a “sell” rating and a $6.00 price target on the stock. The Goldman Sachs Group’s target price would indicate a potential upside of 45.99% from the stock’s current price.

SLN has been the subject of a number of other reports. William Blair reiterated an “outperform” rating on shares of Silence Therapeutics in a research note on Tuesday, November 19th. BMO Capital Markets reiterated an “outperform” rating on shares of Silence Therapeutics in a research note on Monday, December 2nd. HC Wainwright restated a “buy” rating and issued a $75.00 price objective on shares of Silence Therapeutics in a research note on Wednesday, January 29th. Finally, Chardan Capital restated a “buy” rating and issued a $55.00 price objective on shares of Silence Therapeutics in a research note on Tuesday, December 10th. One analyst has rated the stock with a sell rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $45.00.

Silence Therapeutics Stock Down 1.2 %

NASDAQ SLN opened at $4.11 on Tuesday. The stock has a market capitalization of $123.01 million, a PE ratio of -2.62 and a beta of 1.05. The company has a 50 day moving average price of $6.17 and a two-hundred day moving average price of $12.89. Silence Therapeutics has a 12-month low of $4.06 and a 12-month high of $27.72.

Institutional Trading of Silence Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of SLN. Eventide Asset Management LLC bought a new position in Silence Therapeutics during the third quarter worth $11,635,000. Parkman Healthcare Partners LLC increased its position in Silence Therapeutics by 71.8% during the third quarter. Parkman Healthcare Partners LLC now owns 497,870 shares of the company’s stock worth $9,051,000 after acquiring an additional 208,029 shares during the period. Point72 Asset Management L.P. increased its position in Silence Therapeutics by 219.3% during the third quarter. Point72 Asset Management L.P. now owns 467,800 shares of the company’s stock worth $8,505,000 after acquiring an additional 321,300 shares during the period. Janus Henderson Group PLC increased its position in Silence Therapeutics by 32.8% during the third quarter. Janus Henderson Group PLC now owns 1,087,228 shares of the company’s stock worth $19,798,000 after acquiring an additional 268,250 shares during the period. Finally, Verition Fund Management LLC bought a new position in Silence Therapeutics during the third quarter worth $207,000. 98.73% of the stock is currently owned by institutional investors and hedge funds.

Silence Therapeutics Company Profile

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.